explore -WSS

explore

author：Wikipedia 2025-09-06 01:58:32 - browse：12

Novo Nordisk headquarters -- health coverage from STAT — Novo Nordisk's headquarters, outside Copenhagen, Denmark. LISELOTTE SABROE/Scanpix/AFP via Getty Images

Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep up with surging demand, the latest hurdle in its rollout of the weight loss drug.

“To avoid stimulating further demand for this medicine, we’re pausing some key Wegovy promotional efforts,” the Danish drugmaker said in an emailed statement. “We are pausing all local television advertising and postponing planned national television advertising for Wegovy. We are also assessing our promotional efforts to healthcare professionals and adjusting accordingly.” The news was earlier reported by Endpoints.

Wegovy, which contains the active ingredient semaglutide, has become immensely popular for its effectiveness in helping people lose weight and is helping usher in what many see as a sea change in obesity treatment. Its sister drug for diabetes, Ozempic, has also been in demand for a similar effect on weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

WSS

New CMS data security rules will hurt Medicare, Medicaid research

FDA warns medical device makers about rise in fabricated data

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

STAT wants to know your pick for a great summer read or listen

MD Anderson's Padmanee Sharma responds to research credit suit

Surprise medical billing ban raises prices elsewhere

leisure time

explore

focus

23andMe had bad news about my health. I wish a person had delivered it

Hospitals are piloting generative AI tools as regulators play catch

The high cost of giving birth even with insurance

FDA warns medical device makers about rise in fabricated data

As demand for Covid shots wanes, Moderna seeks its next success

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Activists slam private health insurers over coverage restrictions

UpToDate has a racism problem: Dr. Stanley Goldfarb

New air purifier tech could be key to improving indoor air quality

Medicare Advantage enrollment hits roughly 33.4 million

explore

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

Weight loss drugs aren’t covered by Obamacare. That may change

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

How Robert F. Kennedy Jr. distorted vaccine science

The wait for US passports is creating travel purgatory and snarling summer plans

Flagship Pioneering startup Sonata Therapeutics lays off 21

knowledge

entertainment

explore

focus